Resume

Sign in

Research assistant professor

Location:
Chapel Hill, North Carolina, 27599, United States
Salary:
80000
Posted:
July 07, 2009
Email:
zh4yi2@r.postjobfree.com
Contact Info:
***-****** ** ******** **** ****, **** **** ** ****...


ABDELNASER L. REZK, MS, PHD


OFFICE: School of Pharmacy HOME: 6220 Dawn Dr
Kerr Hall, Room 3324 Hurdle Mills, NC
CB 7360 27541
The University of North Carolina (919) ***-****
Chapel Hill, North Carolina
27599-7360
Phone (919) ***-****
Fax (919) ***-****
zh4yi2@r.postjobfree.com


EDUCATION

September 2004 –March 2007 Doctor of Philosophy in Bioanalytical/ Biochemistry
Tanta University Tanta, Egypt
Department of Biochemistry Chemistry
Practical work course
University of North Carolina, at Chapel Hill
Clinical Pharmacology and Analytical Chemistry Laboratory
Pharmacotherapy and Experimental Therapeutics

September 1991–March 1994 Master of Science in Biochemistry
El-Menoufia University, El-Menoufia, Egypt
Faculty of Science
Department of Chemistry and Biochemistry
Practical work course
School of Medicine, El-Menoufia University
Department of Clinical Pharmacology

August 1979 –May 1983 BS of Science in Chemistry
El-Menoufia University, El-Menoufia, Egypt
Faculty of Science

MS Thesis

Title “Determination of theophylline in different body fluids”

Thesis including developing methodologies for Therapeutic Drug monitoring (TDM) of theophylline and other ethylated xanthenes in human body fluids (Blood Plasma, Saliva, and Urine).

PhD Thesis

Title “Simultaneous quantification of antiretroviral medications in human breast milk”

This thesis includes an innovation in clinical biochemistry for accurate and precise measurements of ARV medications in human milk in order to study prevention of HIV transmission in African babies.


EXPERTISE

Over twenty three years of research experience in; clinical pharmacology, pharmaceutical industry and medical technology fields developing new technologies designing biomedical studies and validating research methodologies. Additionally, bioanalytical methods development, validation and bioanalytical applications in clinical pharmacology, drug formulation and drug quality control. Design of chromatography solutions suitable for industry and academia. Qualified speaker and facilitator of professional communication and leadership organizations. Strong interpersonal skills demonstrated with proven ability to collaborate effectively with individuals on all levels.

JOURNAL REVIEWER

1. Journal of Chromatography B. Biomedical sciences and applications (2003-Present).
2. Journal of Chromatography Symposium Volumes 2003.
3. Talanta, Fundamental theory and practice of analytical chemistry Journal (2003-Present).
4. JAOAC INTERNATIONAL (Journal of association of official chemists) Bioanalytical chemistry and Microbiological research. (2003-Present).
5. Journal of Pharmaceutical and Biomedical Analysis (2004-present)
6. Journal of Clinica Chemica Acata (2005-present)
7. Vaccine (2005-present)
8. Informa Health Care (2006-present)
9. Expert Opinion on Pharmacotherapy (2007-present)
10. Analytica Chimica Acta (2008-present)
11. Journal of Current Pharmaceutical Analysis (2008-present)

HONORS AND AWARDS


o 2008: Association of quality assessment in TDM and Clinical Toxicology Certificate (Diamond Level)

o 2007: Association of quality assessment in TDM and Clinical Toxicology Certificate (Diamond Level)

o 2006: The State of North Carolina Governor Award of excellence for Innovation in Science.

o 2006: University of North Carolina at Chapel Hill (UNC-CH) Chancellor Award of excellence for Innovation in Science

o 2006: Association of quality assessment in TDM and Clinical Toxicology Certificate (Diamond Level)

o 2005: Association of quality assessment in TDM and Clinical Toxicology Certificate (Gold Level)


o 2004: Association of quality assessment in TDM and Clinical Toxicology Certificate (Silver Level)


TRAINEESHIP

October 1985 – October 1986 Medical Center
Medical technology training:
Hematology, Biochemistry (clinical biochemistry), Microbiology,
Immunology and Serology

Jun 1996 – Jun 1997 Cannon Research Center
Medical technology training:
Clinical cytogenenetics
Dr. Frank Grass

July 1997 – May 1998 Phlebotomy and Plasmapheresis
Alpha therapeutic corporation
Charlotte, NC


PROFESSIONAL EXPERIENCE

October 2007 – Present Research assistant professor (associate director)
The department of pharmacotherapy and experimental therapeutics, School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, NC

January 2006 – October 07 Research Associate (associate director)
UNC Center for Aids Research (CFAR) Clinical Pharmacology and Analytical Chemistry Core
University of North Carolina at Chapel Hill
Chapel Hill, NC

September 2004 – Jan 2006 Research Associate
School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics
3319 Kerr Hall, CB #7360
The University of North Carolina
Chapel Hill, North Carolina
27599-7360

July 2002 – Sep 2004 Research Analyst
Pharmacotherapy and Experimental Therapeutics
School of Pharmacy, UNC-CH

March 2000 – July2002 Research Specialist
UNC Center for AIDS Research
Clinical Pharmacology/Analytical Chemistry Core
University of North Carolina at Chapel Hill
Dr. ADM Kashuba and Dr. R Tidwell
Chapel Hill, North Carolina
27599-7360

May 1999 – march 2000 Research Scientist
Department of Chemical Discovery
Rhone Poulanc/Avantis RTP, NC

Dec 1998 – May 1999 Formulation Chemist
Department of Drug Development and Formulation
Trimeris Inc., Durham, NC
Dr. MC King

Feb 1998 – July 1998 Analytical Chemist
Department of Quality Control
Vintage Pharmaceutical Inc. Charlotte North Carolina,
J. Spincer

Dec 1996 – Feb 1998 Volunteer Scientist
Department of Clinical Genetics (Cytogenetics Laboratory)
Canon Research Center
Carolina Medical Center, Charlotte, NC

May 1996 – Dec 2000 Part time Plasma Technician/Phlebotomy/team leader
(Plasmapheresis)
Alpha Therapeutic Corporation
Charlotte, NC/Durham, NC

Jun1990 – Dec 1994 Research Associate
Clinical Pharmacology Department
School of Medicine
El-Menoufia University, El-Menoufia, Egypt

May 1986 – Dec 1990 Medical Technologist
Health Care Central Laboratory
Ministry of Health, Cairo, Egypt


PROFESSIONAL AFFILIATIONS

Professional Affiliation:

Fellow: Egyptian Chemical Society 1985-1996

Member: American Chemical Society 1996-Present
Advance for Medical Laboratory Professional 1996-Present
American Association for the Advancement of Science 1996-Present
Toastmaster International 2001-Present
American Association of Colleges of Pharmacy (AACP) 2008-Present.


UNC School of Pharmacy Full time Scientists (Hiring, training, supervising)

2004 – 2005 Shonda White, BS (Research Technician)
2005 – Present Steve Jennings, BS (Research Specialist)
2006 – Present Nicole White, BS (Research Specialist)
2005 – 2007 Jun, Lee, BS (Research Technician)
2006 – Present Tiffany Whiting, BS (Lab Technician)
2006 – 2007 Jisong Kim, BS (Research Technician)
2007 – Present Ruili Wang, MD
2007 – Present Stephanie Malonie, MS
2008 – Present Sunny Qiao, MS


GRANTS and CONTRACTS:


1. Kashuba ADM and Rezk, NL, Principal Investigators, Shimadzu LC/MS Grant for Academic Institutions. 07/2005. $65,000.00

2. Rezk, A H. Principal investigator, Kashuba ADM. Co-Investigator. University of North Carolina Tibotec Therapeutic. Drunavir cervicovaginal secretion study, 03/2008. $140,361.00

3. Rezk, A H. Principal investigator, Kashuab ADM. Co-Principal investigator.
University of North Carolina Conrad “Bioanalytical methods development and validation of UC-781 in rabbit, Human and Monkey” 07/2008 $456,572 7

4. Rezk, A H. Principal investigator, Kashuab ADM. Co-Principal investigator.
University of North Carolina Conrad amendment on “Bioanalytical methods development and validation of UC-781 in rabbit, Human and Monkey” 02/2009 $68,486

Completed Grants and Contracts support (Last 3 Years)


1. Rezk NL, Investigator. Antiretroviral Pharmacology in the Genital Tract. 4/03-2/08. K23 AI54980.
2. Rezk NL, Core Associate Director. General Clinical Research Center. 01/06 – 06/08. M01-RR00046.
3. Rezk, NL, Co-Investigator. The Effect Of Tipranavir/Ritonavir On Steady-State Concentrations Of Omeprazole And Its Metabolites. Boehringer Ingelheim Pharmaceuticals, Inc. 12/2006 – 2/2007. $51,100.00
4. Rezk, NL Co- Investigator, Evaluating the Effects of Tipranavir (with Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity Using a Biomarker Cocktail in Healthy Human Volunteers. Boehringer Ingelheim Pharmaceuticals, Inc. (Investigator-Initiated Research) 2/2006 – 2/2007. $1,668,280.00
5. Rezk, NL, Co-Principal Investigator, Shimadzu LC/MS Grant for Academic Institutions. 07/2005. $65,000.00
6. Rezk, NL, Co-Principal investigator. Adult AIDS Clinical Trials Group. Clinical Pharmacology Support Laboratory. DAIDS (NIH). 1/2004-12/2005. $560,000.00

PUBLICATIONS:

PEER REVIEWED:

1. Rezk NL, White N, Jennings S, Kashuba A, A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma. Talanta, 2009 “accepted”

2. Shouhdary SK, Rezk NL, Ince LW. Cheema M, Zhang L, Su L, Swabstrom R, Kashuba DMA, Margolis D, Suppression of HIV-1 viremia with reverse transcriptase inhibitors, CD4* T Cell recovery, and viral rebound upon therapy interruption in a new model for HIV treatment in the humanized Rag2 -/- Уc -/- mice, JOV.2009 “in press”

3. Kwara A, Lartey M, Lartey M, Boamah I, Rezk NL, Court M., Oliver-Commey J, Kenu E, Kashuba A, Court M, Interindividual Variability in Pharmacokineticks of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV Co-infected Ghanaian patients, JCP.2009 “in press”

4. Legar P, Dillingham R, Beauhainrais C, Kashuaba A, Rezk NL, Fitzgerald D Court Pape J Haas D, CYP2B6 Variants and Plasma Efavirenz Concentration during Antiretroviral Therapy in Port-a—Prince, Haiti, JID, 2009 “in press”

5. Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvagis M., Horton AL, Fiscus SA, Patterson KB, Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs during and after Pregnancy in HIV-1 infected Women, Antimicrob Agents Chemother, 2009 “in press”

6. Choi SO, Rezk NL, Kim J. Kashuba ADM, Development of a LC-MS method for measuring TNF in human vaginal tissue. JCS 2009 “in press”

7. Kwara A, Lartey M., Kwamena Sagoe, Rezk NL, Court M., CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. BJCP.2009 “in press”

8. Rezk NL, White N, Kashuba A, An accurate and precise high performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. Anal Chim Acta, 2008 Nov3:628(2):204-13

9. Rezk NL, White N, Bridges AS, Abdel-Megeed MF, Mohamed TM, Moselhy SS, Kashuba AD. Studies on Antiretroviral Drug Concentrations in Breast Milk: Validation of a Liquid Chromatography-Tandem Mass Spectrometric Method for the Determination of 7 Anti-Human Immunodeficiency Virus Medications Ther Drug Monit, 2008 Aug 27.

10. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.. PLoS Med. 2008 Aug 5;5(8):e157; discussion e157.
11. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, P, Rezk NL, Kashuba A, Anton P, McGowan, Shattock R, Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel, PLoS Medicine 2008 August 5;8: 165-167.

12. DiCenzo R, Peteson D, Cruttenden K, Mariuz P, Rezk NL, Hochreiter J, Gelbard H, Schifitto G. Effect of minocycline and valporic acid coadministration on atazanavir plasma concentrations in HIV-ifectd adults receiving atazanavir/Ritonavir, Antimicrob. Agents Chemother. 2008 Jun 23.

13. Tappouni A, Rublein JC, Donovan BJ, Hollowell SB, Tien HC, Min SS, Theodore D, Rezk NL, Smith PC, Tallman MN, Raasch RH, Kashuba AD. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir, Am J Health Syst Pharm. 2008 Mar 1:65 (5):422-128.

14. Kwara A, DeLong A, Rezk NL, Hogan J, Burtwell H, Champan S, Moreira C, Kurpewski J, Ingersoll J, Caliendo A, Kashuba A, Susan Cu-Uvin, Antiretroviral Drug Concentrations and Virologic Rebound in the Genital Tract of HIV-Infected Women, Clin Infect Dis. 2008 Mar 1;46(5):719-25.

15. Vourvahis M, Tappouni H, Patterson K, Chen Y, Rezk NL, Fiscus S, Kearney B, Rooney J, Hui J, Cohen M, Kashuba A, Tenofovir Pharmacokinetics in the Genital Tract: Implication for Transmission Prevention, JAIDS,2008 (In press)

16. Dumond J, Yeh R., Patterson K, Corbett A, Jung B, Rezk NL, Bridges A, Stewart P, Cohen M, Kashuba ADM, Antiretroviral Drug Exposure in the Female Genital Tract: Implications for Oral Pre-and Post-Exposure Prophylaxis, AIDS, 2007 Sep 12:21(14):1899-907.

17. Rezk NL, Abdel-Megeed M, Kashuba ADM. Development of a highly efficient extraction technique and specific multiplex assy for measuring drug concentrations in breast milk. Ther Drug Monit, 2007 Aug 29(24):429-36.

18. Jung BH, Rezk NL, Bridges AS, Kashuba ADM, Simultaneous determination of 16 antiretroviral drugs in human plasma for quantitative analysis with liquid

19. Hosseinipour MC, Corbett AH, Kanyama C, Mshali I, Phakati S, Rezk NL, Van der Horst C, Kashuba ADM. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian subjects. AIDS, 21;1 (2007) 59-64.

20. Choi SO, Rezk NL, Kashuba ADM, High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications
J Pharm Biomed Anal. 43 ( 2007) 1562-1567.

21. Rezk NL, Brown, K, Kashuba, ADM, A simple and sensitive bioanalytical assay for simultaneous quantitative determination of omeprazole and its three metabolites in human blood plasma using RP- HPLC after an optimized liquid-liquid extraction procedure. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Aug 18; [Epub ahead of print]

22. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Klein C, Rublein J, Kashuba ADM. Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes (CYP) 2C9, CYP2C19, and CYP1A2, but Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers. JAIDS 2006; 42:52-60.

23. Rezk N, Crutchley R, Yeh RF, Kashuba ADM. Full Validation of an Analytical Method For The HIV Protease Inhibitor Atazanavir In Combination With 8 Other Antiretroviral Agents and Its Applicability to Therapeutic Drug Monitoring. Ther Drug Monit, 2006 Aug;28(4):517-25.

24. Rezk NL, Crutchley RD, Kashuba ADM. Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction, Journal of Chromatography B 2005; 822:201-208.

25. Min SS, Corbett AH, Rezk N, Cu-Uvin S, Fiscus SA, Petch L, Cohen MS, Kashuba ADM. Protease inhibitor and Nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1 infected women. J AIDS 2004; 37(5):1577-1580.

26. Rezk NL, Tidwell RR, Kashuba ADM. High-Performance Liquid Chromatography Assay For The Quantification Of HIV Protease Inhibitors And Non-Nucleoside Reverse Transcriptase Inhibitors In Human Plasma J Chromatography B Analyt Technol Biomed Life Sci 2004;805(2):241-247.

27. Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba ADM, The Pharmacokinetics, Safety, and Initial Virologic Response of A Triple-Protease Inhibitor Salvage Regimen Containing Amprenavir, Saquinavir, and Ritonavir, J Acquir Immune Defic Syndr 2004;36:921–928.

28. Rezk NL, Tidwell RR, Kashuba ADM. Simultaneous Determination of Six HIV Nucleoside Analogue Reverse Transcriptase Inhibitors and Nevirapine By Liquid Chromatography With Ultraviolet Detection After Solid-Phase Extraction. J Chromatography B 2003; 791:137–147.

29. Rezk NL, Tidwell RR, Kashuba ADM. Simple and rapid quantification of the nonnucleoside reverse transciptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet detection. J Chromatography B 2002; 774 (1);79-88.


SCIENTIFIC ABSTRACTS:

1. Corbett A., Martinson F., Rezk N, Kashuba A., Jamieson D., Chasela C., Kayira D., Tegha G., Kamwendo D., Van Der Horst C., The BAN Study Team. Lopinavir/Ritonavir Concentrations in Breast Milk and Breast-feeding infancts. 16th Conference on Retroviruses and Opportunistic Infections Montréal, CA, Feb 2009.

2. Kawara A, Lartey M., Boamah I., Rezk N, Oliver-Commey J., Kenu E., Kashuba A., Court M., Variability in the pharmacokinetics of NRTI in TB/HIV Co-infected Patients. 16th Conference on Retroviruses and Opportunistic Infections Montréal, CA, Feb 2009.

3. Rezk NL, White N, Bridges A, Abdel-Megeed MF, Mohamed T, Moselhy S, Kashuba A, Innovation in Analytical Chemistry: Promoting the HIV Prevention and Treatment Agenda. BIT’s 1st Annual World Summit of Antiviral, Kunming, China July 2008.

4. Schwartz J, Kashuba A, Rezk N, Nasution M, Choi SO, Kim JS, Brache V, Poindexter A, Creinin M, Ju S, Cochon L, Taylor D, Mauck C. Preliminary results from a pharmacokinetic study of the candidate vaginal microbicide agent 1% tenofovir gel, American society for clinical pharmacology and therapeutics annual meeting, Orlando,FL, 2-5 April 2008.

5. K. Ilic, G. Hogeland, N. Rezk, N. White, J. Lamba, C. Lee, ADM. Kashuba, EG. Schuetz, CM. Lindley, ML. Chen, RL. Hawke, The influence of sex, race/ethnicity and CYP 2B6 genotype on bupropion (B) metabolism. American society for clinical pharmacology and therapeutics annual meeting, Orlando,FL, 2-5 April 2008.

6. Kevin C Brown, Mina C Hosseinipour, Janelle M Hoskins, Haiaso-Chuan Tien, Rezk NL., Peter Kazemba, Ralf Weigel, Howard L Mcleod, Angela DM Kahsuba, Amanda H Corbett. Correlations between Drug Metabolizing Enzyme and Drug Transporter Genotypes and Nivirapine Eposure in HIV-Infected Malawian Adults and Childeren.Antiretroviral Drug Concentrations in Breast Milk and Breastfeeding Infants. . 9th International workshop of clinical pharmacology of HIV, NewOrleans , April 2008

7. Corbett A., Kashuba A., Rezk NL., Jamieson D, Chasela C., Hyde L., Yusuf Ahmed Y., Tegha G., Joaki G, Kamwendo D, van der Horst C., and the BAN Study Team. Antiretroviral Drug Concentrations in Breast Milk and Breastfeeding Infants. 15th Conference on Retroviruses and Opportunistic Infections Boston, MA, Feb 2008.

8. Vourvahis, M, Dumond J, Patterson K, Rezk N, Hsiao T, Li J, Choi S, White N, Drulak M, Sabo J, Castles M, MacGregor T, Kashuba A. Effects of Tipranavir/ritonavir (TPV/r) on the Activity of Cytochrome P450 (CYP) Enzymes 1A2, 2C9, and 2D6 in healthy Volunteers. 8th International workshop of clinical pharmacology of HIV, Budapest, April 2007

9. Vourvahis, M, Dumond J, Patterson K, Rezk N, White N, Jennings S, Tien H, Sabo J, MacGregor T, Kashuba A. Effects of Tipranavir/ritonavir (TPV/r) on the Activity of Hepatic and Intestinal Cytochrome P450 3A4/5 and P-glycoprotein (Pgp): Implications for Drug Interaction. Abstr L-150. 14th Conference on Retroviruses and Opportunistic Infections Los Angeles, CA, Feb 2007.

10. Cu-Uvin S, DeLong A, Rezk N, Jogan J, Burtwell H, Chapman S, Moreira C, Kurpewski J, Ingersoll J, Caliendo A, Kashuba A. Antiretroviral Drug Concentrations in the Genital tract of HIV-Infected Women. Poster # 778. 14th Conference on Retroviruses and Opportunistic Infections Los Angeles, CA, Feb 2007

11. Dumond J, Yeh R, Patterson K, Corbett A, Jung BH, Rezk N, Bridges A, Dempsey E, Cohen M, Kashuba ADM. First Dose and Steady-State Genital Tract Pharmacokinetics of Ten Antiretroviral Drugs in HIV-Infected Women: Implications for Pre- and Post-Exposure Prophylaxis 13th Conference on Retroviruses and Opportunistic Infections Denver, CO, Feb 2006

12. Vourvahis M, Tappouni H, Patterson K, Chen YC, Rezk N, Fiscus S, Kearney BP, Rooney JF, Cohen MS, Kashuba ADM. A Pharmacologic Basis for the Use of Tenofovir In Pre- and Post-Exposure Prophylaxis: Intra and Extracellular Genital Tract Pharmacokinetics and Pharmacodynamics from First Dose to Steady State in HIV-1 Infected Men and Women 13th Conference on Retroviruses and Opportunistic Infections Denver, CO, Feb 2006

13. Corbett A, Mosseinipour M, Nyirenda J, Kanyama C, Mshali I, Chinyama S, Lyke A, Rezk N, Tien H, Hoffman I, Kashuba A, Mwansambo C, Weigel R, Kazembe P. Pharmacokinetics between trade and generic liquid and split tablet formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian Children. 2005 Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract #H-1106

14. Yeh RF, Gaver VE, Park JJ, Patterson KB, Rezk N, Baxter-Meheux F, White N, Eron JJ, Klein CE, Rublein J, Kashuba ADM. Lopinavir/ritonavir inhibits intestinal CYP3A Activity to a Greater Extent than Hepatic CYP3A activity Using Midazolam as a Biomarker in Healthy Human Volunteers. 6th International Workshop on Clinical Pharmacology in HIV Therapy. Quebec City, Quebec, April 2005.

15. International Workshop on Clinical Pharmacology of HIV Therapy, Washington DC 2002.


WEB SCIENTIFIC& TECHNICAL ARTICLES:

1- Naser L. Rezk, SPE-HPLC method for HIV integrase inhibitors, Separation Science, (2008).
http://www.sepscience.com/News/SPE-HPLC-method-for-HIV-integrase-inhibitors.aspx

Professional Skills (Scientific):

1. Developing, validating and applying analytical methods of bioorganic compounds.
2. Designing extraction methods for drugs and drug metabolites in biological matrices.
3. Multi-step design of analytical assays of HIV drugs in different biological fluids such as plasma, serum, and saliva, urine, cervicovaginal secretions, semen, tissue and breast milk.
4. Analytical thinking and problem-solving skills in the design and planning of research projects.
5. Designing analytical methods for quantification of multiple drugs in one sample.
6. Organizing laboratory activities to meet quality assurance principles and achieve high accuracy.


Professional Skills (Technical):

1. Bioanalyical chemistry using HPLC in assaying HIV drugs in different body fluids
2. Drug formulation research using HPLC, osmometer, turbidometer, rheometer and potentiometry (pH meter, ion selective electrodes)
3. Medical research using automated analytical systems: General chemistry, immunoasspatineceelectrophoresis with various support media, and radioisotopes.
4. Therapeutic drug monitoring for ARV’s, Theophylline and psychoactive drugs.
5. Medical technology experience analyzing blood chemistry (liver function tests, kidney function, lipid profiles, protein profiles), hematology tests including cell count and hemoglobin
6. Proficient with spectrophotometry (photometry (UV-VIS-IR), atomic absorption, fluorescence and flame emission in medical research.
7. Drug formulation experience
8. Animal research experience
9. Phlebotomy experience.
10. Proficient with computer (Word Processor, Excel, Access, Power Point, Publisher, ChemDrew Plus, Science Finder, Adobe Photoshop, and Scientific Databases.


Professional Skills (Management& Communication):


1. Excellent management skills; supervise three analytical chemists
2. District officer of professional communication and leadership organization
3. Promote vital skills of self-actualization, enhance leadership potential, and foster human understanding through personal goal setting.
4. Provide a mutually supportive and positive learning environment in which every person has the opportunity to develop communication and leadership skills, which in turn foster self-confidence and personal growth.
5. Qualified speaker and facilitator of professional communication and leadership organization.
6. Strong interpersonal skills demonstrated with proven ability to collaborate effectively in positive attitude with individuals on all levels.
7. Promote the art of speaking, listing and thinking.
8. Fluent in Arabic and English; knowledge of German and French.


SELECTED PRESENTATIONS:


1. “Innovation in Analytical Chemistry to promote the HIV Prevention and Treatment Agenda”
BIT’s 1st Annual World Summit of Antivirals, Kunming, China,
July, 2008.

2. “Determination of Drug Concentrations in Human Breast Milk”
CFAR Seminar Series
School of Medicine, UNC, Chapel Hill
May, 2007

6. “Quantification of Antiretroviral Medication in Human Breast Milk”
Pharmacotherapy & Experimental Therapeutics Seminar Series
School of Pharmacy, UNC, Chapel Hill
September, 2006

5. “Bioanalytical Method Development Column Selection and Innovation”
Clinical Pharmacology and Analytical Chemistry Laboratory
Research group meeting
School of Pharmacy, UNC, Chapel Hill
Jun, 2006

4. “Quality Assurance/Quality Control and Good Clinical Laboratory Practice GCLP”
Clinical Pharmacology and Analytical Chemistry Laboratory
Research group meeting
School of Pharmacy, UNC, Chapel Hill
March 2005

3. “Biomedical Assay Validation, Theory and Laboratory Practice”
Pharmacotherapy& Experimental Therapeutics Seminar Series
School of Pharmacy, UNC, Chapel Hill
March 2004